Immunology Specialist Khartis Therapeutics Emerges from Stealth with $95M
Importance · 4/5Sources · 1
What happened
Khartis Therapeutics emerged from stealth with $95 million in funding, including a $50 million Series B led by Forge Life Science Partners and participation from Lilly Asia Ventures. Co-founded in 2024 by former Pfizer executive Robert Hoffman, the company focuses on oral small molecule medicines for immunology pathways, specifically targeting Thyroid Eye Disease (TED).
Why it matters
The company aims to provide a safer, oral, and patient-friendly alternative to current intravenous treatments for TED, such as Amgen's Tepezza and Viridian's Lumvoa, which carry safety trade-offs like hearing issues and blood sugar spikes.
Notes
- unsupported-claim:Hoffman co-founded XinThera before Gilead's acquisition
- unsupported-claim:XinThera was acquired by Gilead for an undisclosed sum in 2023
Sources
Immunology specialist Khartis Therapeutics emerges from stealth with $95m - Pharmaceutical Technology
www.pharmaceutical-technology.com · Published: Aug 14, 2026, 8:00 AM